|Bid||16.93 x 1000|
|Ask||16.94 x 800|
|Day's Range||16.61 - 17.77|
|52 Week Range||10.22 - 39.50|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Evolus Inc. has already reached 2,000 doctors with a new app and plans to expand that to 3,000 before the launch of its medicine, Jeuveau, next week. The app includes a 90-day program to start physicians with free samples to encourage more use, Chief Executive Officer David Moatazedi said in an interview at the company’s analyst day in New York. Allergan, meanwhile, is mired in debate about its long-term strategy even as Botox sales are handily beating analyst estimates.
The best pharmaceutical stocks to buy have commonalities: Strong Composite Ratings and Relative Strength Ratings.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Evolus, Inc. (NASDAQ:EOLS) should be aware of the most powerful shareholder groups...
Within Pharmacy Services, despite a fierce pricing competition, CVS Health (CVS) is currently riding on high level of service and execution, competitive pricing and a unique integrated model.
These three health and technology stocks are seeing technical strength ahead of upcoming earnings. Evolus, Inc. (NASDAQ: EOLS ) gained 50 cents to $26.44 on 537,100 shares Wednesday. The performance beauty ...
Evolus Inc. (EOLS) gained 50 cents to $26.44 on 537,100 shares traded Wednesday. The performance-beauty company said it will release earnings after the close of the stock market April 30. Extreme Networks Inc. (EXTR) rose 29 cents to $8.26 on 2.1 million shares traded Wednesday, nearly 1 1/2 times its average volume.
With Zimmer Biomet (ZBH) focusing solely on this restructuring initiative, chances are slim for the company to post promising growth performances across its operating segments.
Within Covance Drug Development, LabCorp (LH) is expected to drive profitable growth through expanded solutions and enhanced operational capabilities.
ConforMIS (CFMS) expects to register solid revenue growth on robust performance by its product lines as well as steady royalties.
Hill-Rom (HRC) consistently reports strong Core revenue growth in domestic and international markets on solid segmental performance.
Strong performance across Renal Care, Clinical Nutrition, Advanced Surgery and Acute Therapies businesses might aid Baxter (BAX) in Q1. However, lower sales at Pharmaceutical business might be a woe.
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
Evolus, Inc.'s (NASDAQ:EOLS): Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. With the latest financial year loss of -US$4.5m and a trailing-twelve monthRead More...
Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.
In his second "Executive Decision" segment of Mad Money Thursday night, Jim Cramer sat down with David Moatazedi, president and CEO of Evolus Inc. with a new drug to compete with Botox. Shares of EOLS have surged from $16 to $29 after the company received FDA approval on Friday.